Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Harris Taylor C. reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Harris Taylor C. reported two equity awards of stock units under the company’s 2018 Equity Incentive Plan. One award covers 1,281 stock units, vesting in three equal annual installments on each yearly anniversary of the grant date, subject to continued service. A separate award covers 1,949 stock units, vesting in full on the earlier of June 24, 2027 or the day prior to the company’s next annual meeting of stockholders, also subject to continued service. Following the first transaction, Taylor’s reported direct holdings in common shares were 3,230 shares, and following the second, 1,949 shares are reported in that line item.
ESTABLISHMENT LABS HOLDINGS INC. filed an initial Form 3 for director Harris Taylor C. This filing identifies him as a director but shows no reported transactions or derivative positions. It functions as a baseline disclosure of his status as an insider without detailing specific share holdings.
Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors, effective immediately, to serve until the 2027 annual meeting of shareholders. He will also sit on the Audit Committee and the Nominating and Corporate Governance Committee.
Harris will receive the company’s standard non-employee director cash and equity compensation, including an updated initial equity grant of $170,000 for new directors and a $170,000 annual equity grant. The Board determined that all members of the Audit, Compensation, and Nominating and Corporate Governance Committees meet Nasdaq independence standards.
The accompanying press release highlights Harris’s 25+ years of experience in healthcare and medical technology, including leadership roles at Cutera, MyoKardia, Zeltiq Aesthetics, and Thoratec, and his involvement in major strategic transactions such as MyoKardia’s $13.1 billion acquisition by Bristol Myers Squibb.
Issuer filed a Form 144 reporting a proposed sale of 24,198 common shares via a stock option exercise on 06/15/2026, with cash as the payment method. The filing also lists multiple prior open-market dispositions by Sariel Group Ltd dated between 03/23/2026 and 05/06/2026, including sales such as 37,500 shares for $2,446,050 on 04/14/2026. The notice documents the method and per‑trade amounts for these recent dispositions.
JW Asset Management–affiliated funds sold Establishment Labs shares and fell below a 10% ownership threshold. JW Partners and JW Opportunities Fund sold a total of 90,533 common shares in open-market trades on May 26–28, 2026 at prices around $72–$74 per share. After these sales, the reporting group indirectly held 2,890,582 shares. The Form 4 states this transaction caused the reporting persons to cease being beneficial owners of more than 10% of Establishment Labs’ common stock, and it is described as their final Form 4 for this issuer. The advisor and related entities disclaim beneficial ownership beyond their indirect pecuniary interests.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an award of 2,354 common share stock units as compensation. The units were granted at a stated price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
The shares subject to this award vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, as long as Slotkin continues as a service provider through that date. After this grant, he directly holds 32,610 common shares.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received an equity award of 2,354 common share units on May 22, 2026, at no cash cost to him. This grant was made under the company’s 2018 Equity Incentive Plan as part of his director compensation.
The stock units vest in full on the earlier of May 22, 2027 or the day before the company’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this award, Schutter directly holds 177,736 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. reported that director Ann Custin received an award of 2,354 common share stock units as equity compensation. The award was granted at no cash cost and increases her direct holdings to 24,086 common shares. The units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she continues as a service provider through that date.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received an award of 2,354 common share units at no cost under the company’s 2018 Equity Incentive Plan. The units vest in full on the earlier of May 22, 2027 or the day before the next annual meeting, if he continues as a service provider.
Following this grant, he holds 1,079,669 common shares directly and 19,090 common shares indirectly through his spouse.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Leslie Gillin received an award of 2,354 common share stock units as compensation. The award was granted at no cash cost to her and is tied to continued board service. These units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she remains a service provider through that date. Following this grant, she holds 18,398 common shares directly.